MedPath

Using Micro Electro Mechanical Systems to Detect the Air of Vaginal Discharge

Not Applicable
Recruiting
Conditions
Vaginal Infection
Vaginitis
Registration Number
NCT05557318
Lead Sponsor
Taiwan Carbon Nano Technology Corporation
Brief Summary

This clinical study aims to train the algorithm and assess the performance of the Ainos Flora Women's Vaginal Health Tester in identifying vaginal infections.

Detailed Description

Ainos Flora Women's Vaginal Health Tester is an in vitro diagnostic device implementing electronic nose technology to detect vaginal infections by examining metabolized gases of vaginal bacteria. The electronic nose system mainly comprises the Micro-Electro-Mechanical Systems (MEMS) gas sensor array and the Artificial Neural Network algorithm. The primary purpose of this study is to train the algorithm and assess the performance of the Ainos Flora in identifying vaginal infections. In addition, the primary outcome measures of this study, including sensitivity and specificity, will be used as a reference for the feasibility and sample size assessment of the next phase of pivotal clinical trials.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
120
Inclusion Criteria
  • Female, Age ≥20 to ≤50.
  • Have had sexual experience.
  • Fully understand the subject's informed consent process and be willing to undergo all study-related assessments and procedures.
Exclusion Criteria

Women who meet any of the following criteria by participant report will be excluded from the study:

  • During menstruation.
  • Have performed vaginal washing within three days.
  • Have been treated for vaginal infections within one week.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
To assess the sensitivity and specificity of Ainos Flora in subjects compared to RT-PCR and culture groups in identifying the types of vaginitis.Up to 6 months.

* Bacterial infection : Bacterial vaginosis (BV) / Escherichia coli / Trichomonas / Group B streptococcus / Chlamydia trachomatis / Neisseria gonorrhea

* Fungal infection: Candida albicans

* Mixed infection: Bacterial and fungal infections coexist

* No infection: Healthy participant

Secondary Outcome Measures
NameTimeMethod
Assess the change in specificity as the number of subjects is changed.Up to 6 months.

When the number of subjects reaches 30,60,90,120, input the collected gas data into the algorithm and calculate the specificity. We can then assess the change in specificity when the number of subjects changes from 30 to 60, 90, and 120.

Assess the change in sensitivity as the number of subjects is changed.Up to 6 months.

When the number of subjects reaches 30,60,90,120, input the collected gas data into the algorithm and calculate the sensitivity. We can then assess the change in sensitivity when the number of subjects changes from 30 to 60, 90, and 120.

Trial Locations

Locations (2)

MacKay Memorial Hospital

🇨🇳

Taipei, Taiwan

Tri-Service General Hospital

🇨🇳

Taipei, Taiwan

MacKay Memorial Hospital
🇨🇳Taipei, Taiwan
Dr. Wen-Chu Huang
Principal Investigator
Dr. Chia-Sui Weng
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.